|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP2270150B2
(en)
|
1999-04-09 |
2019-08-07 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US20020177571A1
(en)
*
|
2000-11-29 |
2002-11-28 |
Gordon Erlinda M. |
Targeted vectors for cancer immunotherapy
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20070178066A1
(en)
*
|
2003-04-21 |
2007-08-02 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
US20090123428A1
(en)
*
|
2003-04-21 |
2009-05-14 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
US8052966B2
(en)
*
|
2003-04-21 |
2011-11-08 |
University Of Southern California |
Methods and compositions for treating metastatic cancer
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
AU2005244058B2
(en)
|
2004-05-10 |
2011-07-28 |
Macrogenics, Inc. |
Humanized FcgammaRIIB specific antibodies and methods of use thereof
|
|
WO2006085967A2
(en)
*
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
GEP20105059B
(en)
|
2004-07-26 |
2010-08-10 |
Biogen Idec Inc |
Anti-cd154 antibodies
|
|
DK2213683T3
(da)
|
2004-08-04 |
2013-09-02 |
Mentrik Biotech Llc |
VARIANT-Fc-REGIONER
|
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
|
EP2325206B1
(en)
*
|
2004-11-12 |
2014-03-19 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US20100104564A1
(en)
*
|
2005-03-29 |
2010-04-29 |
Genevieve Hansen |
Altered Antibody Fc Regions and Uses Thereof
|
|
ES2971647T3
(es)
|
2005-04-15 |
2024-06-06 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2012018687A1
(en)
|
2010-08-02 |
2012-02-09 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
AU2006265936A1
(en)
*
|
2005-07-01 |
2007-01-11 |
Medimmune, Llc |
An integrated approach for generating multidomain protein therapeutics
|
|
WO2007008943A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
CA2618681C
(en)
|
2005-08-10 |
2015-10-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
CA2625619A1
(en)
|
2005-10-14 |
2007-04-26 |
Medimmune, Inc. |
Cell display of antibody libraries
|
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
|
IN2014DN10515A
(cg-RX-API-DMAC10.html)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
|
PT2029173T
(pt)
|
2006-06-26 |
2016-11-02 |
Macrogenics Inc |
Anticorpos específicos fc rib e seus métodos de uso
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
AU2013202392B2
(en)
*
|
2006-12-20 |
2016-02-25 |
Mmrglobal, Inc. |
Antibodies and methods for making and using them
|
|
EP2121756A4
(en)
*
|
2006-12-20 |
2011-08-31 |
Mmrglobal Inc |
ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
|
|
BR122020022640B1
(pt)
|
2007-03-22 |
2022-03-29 |
UCB Biopharma SRL |
Molécula de dna codificando proteínas de ligação a cd154, vetor, célula hospedeira e método de produção das referidas proteínas
|
|
MX2009011996A
(es)
|
2007-05-07 |
2010-04-21 |
Medimmune Llc |
Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica.
|
|
CA2694488A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
NZ583931A
(en)
|
2007-08-17 |
2012-06-29 |
Purdue Research Foundation |
Psma binding ligand-linker conjugates and methods for using
|
|
JP5334319B2
(ja)
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
|
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
|
EP2604628A3
(en)
|
2007-12-21 |
2013-08-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4R) - 173
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
ES2742268T3
(es)
|
2007-12-26 |
2020-02-13 |
Xencor Inc |
Variantes de Fc con unión alterada a FcRn
|
|
JP2011509675A
(ja)
|
2008-01-18 |
2011-03-31 |
メディミューン，エルエルシー |
部位特異的コンジュゲーションのためのシステイン操作抗体
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
US8802093B2
(en)
|
2008-04-02 |
2014-08-12 |
Macrogenics, Inc. |
HER2/neu-specific antibodies and methods of using same
|
|
US8669349B2
(en)
|
2008-04-02 |
2014-03-11 |
Macrogenics, Inc. |
BCR-complex-specific antibodies and methods of using same
|
|
WO2009125825A1
(ja)
|
2008-04-11 |
2009-10-15 |
中外製薬株式会社 |
複数分子の抗原に繰り返し結合する抗原結合分子
|
|
WO2009129538A2
(en)
*
|
2008-04-18 |
2009-10-22 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
|
US7919273B2
(en)
*
|
2008-07-21 |
2011-04-05 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
BRPI0914091B1
(pt)
*
|
2008-10-14 |
2022-05-10 |
Genentech Inc |
Igg variante, composição farmacêutica, kit e usos de um igg variante
|
|
CA2743469C
(en)
|
2008-11-12 |
2019-01-15 |
Medimmune, Llc |
Antibody formulation
|
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
TR201804897T4
(tr)
|
2009-10-07 |
2018-06-21 |
Macrogenics Inc |
Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
|
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
|
US9951324B2
(en)
|
2010-02-25 |
2018-04-24 |
Purdue Research Foundation |
PSMA binding ligand-linker conjugates and methods for using
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
LT2542256T
(lt)
|
2010-03-04 |
2019-10-25 |
Macrogenics Inc |
Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
|
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
EP2603526A1
(en)
|
2010-08-13 |
2013-06-19 |
Medimmune Limited |
Monomeric polypeptides comprising variant fc regions and methods of use
|
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
AU2011299066A1
(en)
|
2010-09-10 |
2013-03-21 |
Apexigen, Inc. |
Anti-IL-1 beta antibodies and methods of use
|
|
CN103347537A
(zh)
*
|
2010-10-20 |
2013-10-09 |
莫弗泰克股份有限公司 |
抗叶酸受体α抗体糖型
|
|
PT2647707T
(pt)
|
2010-11-30 |
2018-11-15 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de toxicidade
|
|
EP4231014A3
(en)
|
2010-11-30 |
2024-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
|
HUE053720T2
(hu)
|
2011-01-14 |
2021-07-28 |
Univ California |
ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
|
|
US20140088019A1
(en)
|
2011-02-11 |
2014-03-27 |
Zyngenia, Inc. |
Monovalent and Multivalent Multispecific Complexes and Uses Thereof
|
|
CA2827923C
(en)
|
2011-02-25 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc antibody
|
|
MX342810B
(es)
|
2011-03-03 |
2016-10-13 |
Apexigen Inc |
Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
|
|
EP2683740B1
(en)
|
2011-03-10 |
2018-07-04 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
ES2676499T3
(es)
|
2011-04-13 |
2018-07-20 |
Bristol-Myers Squibb Company |
Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
|
|
US8778345B2
(en)
|
2011-04-29 |
2014-07-15 |
Apexigen, Inc. |
Anti-CD40 antibodies
|
|
MX347818B
(es)
|
2011-05-21 |
2017-05-15 |
Macrogenics Inc |
Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
|
|
CA2837169C
(en)
|
2011-05-24 |
2021-11-09 |
Zyngenia, Inc. |
Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
|
|
MX340498B
(es)
|
2011-06-30 |
2016-07-11 |
Chugai Pharmaceutical Co Ltd |
Polipeptido heterodimerizado.
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
AU2012295394B2
(en)
|
2011-08-12 |
2016-04-14 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
|
RU2722829C9
(ru)
|
2011-09-30 |
2020-09-22 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень
|
|
PE20142361A1
(es)
|
2011-09-30 |
2015-01-16 |
Dana Farber Cancer Inst Inc |
Peptidos terapeuticos
|
|
TW201817745A
(zh)
*
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
CA2850194C
(en)
*
|
2011-09-30 |
2023-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
|
CA2854153A1
(en)
|
2011-11-02 |
2013-05-10 |
Apexigen, Inc. |
Anti-kdr antibodies and methods of use
|
|
EP2776061B1
(en)
|
2011-11-07 |
2019-08-14 |
MedImmune, LLC |
Multispecific and multivalent binding proteins and uses thereof
|
|
CN104080909A
(zh)
|
2011-11-30 |
2014-10-01 |
中外制药株式会社 |
包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
|
|
EP2794653B1
(en)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
|
KR102041412B1
(ko)
*
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
CN104204204A
(zh)
|
2012-02-09 |
2014-12-10 |
中外制药株式会社 |
抗体的Fc区变异体
|
|
TWI877445B
(zh)
|
2012-02-24 |
2025-03-21 |
日商中外製藥股份有限公司 |
經FcγRIIB促進抗原消失之抗原結合分子
|
|
JP6280031B2
(ja)
|
2012-03-29 |
2018-02-14 |
中外製薬株式会社 |
抗ｌａｍｐ５抗体およびその利用
|
|
ES2856272T3
(es)
|
2012-05-30 |
2021-09-27 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígenos para eliminar antígenos agregados
|
|
CN104487457B
(zh)
|
2012-05-30 |
2018-01-26 |
中外制药株式会社 |
靶组织特异性抗原结合分子
|
|
ES2758979T3
(es)
*
|
2012-07-06 |
2020-05-07 |
Genmab Bv |
Proteína dimérica con mutaciones triples
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
CN104428315B
(zh)
|
2012-07-13 |
2017-09-29 |
罗氏格黎卡特股份公司 |
双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
|
|
EP2889376A4
(en)
|
2012-08-24 |
2016-11-02 |
Chugai Pharmaceutical Co Ltd |
MOUSE FC RII SPECIFIC FC ANTIBODY
|
|
DK2889377T3
(da)
*
|
2012-08-24 |
2020-03-30 |
Chugai Pharmaceutical Co Ltd |
Fc?RIIb-Specifik Fc-regionsvariant
|
|
CN110066335B
(zh)
|
2012-10-30 |
2024-04-05 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
HK1211599A1
(en)
|
2012-11-08 |
2016-05-27 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonists and uses thereof
|
|
EP3875082A1
(en)
|
2012-11-15 |
2021-09-08 |
Endocyte, Inc. |
Conjugates for treating diseases caused by psma expressing cells
|
|
CN111961134B
(zh)
|
2012-12-10 |
2024-04-05 |
比奥根Ma公司 |
抗血液树突细胞抗原2抗体及其用途
|
|
TWI693073B
(zh)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
|
|
EP3557260B1
(en)
|
2012-12-21 |
2022-05-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
|
|
JP6433297B2
(ja)
|
2012-12-27 |
2018-12-05 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
KR20160007478A
(ko)
*
|
2013-01-10 |
2016-01-20 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
EP2956468B1
(en)
|
2013-02-12 |
2020-06-10 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
EP3617220B1
(en)
|
2013-02-12 |
2021-03-24 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
SI2968520T1
(sl)
|
2013-03-14 |
2022-01-31 |
Macrogenics, Inc. |
Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor
|
|
JP6397479B2
(ja)
|
2013-03-15 |
2018-09-26 |
エータイアー ファーマ， インコーポレイテッド |
ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート
|
|
MX2015013163A
(es)
|
2013-03-15 |
2016-04-04 |
Zyngenia Inc |
Complejos multiespecificos multivalente y monovalentes y sus usos.
|
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
WO2014144466A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
KR20150128796A
(ko)
|
2013-03-15 |
2015-11-18 |
바이오젠 엠에이 인코포레이티드 |
항-알파 v 베타 5개 항체를 이용한 급성 신장 손상의 치료 및 예방
|
|
NZ629816A
(en)
|
2013-03-15 |
2017-07-28 |
Dana Farber Cancer Inst Inc |
Therapeutic peptides
|
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
|
WO2014208482A1
(ja)
|
2013-06-24 |
2014-12-31 |
中外製薬株式会社 |
ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
WO2015031673A2
(en)
|
2013-08-28 |
2015-03-05 |
Bioasis Technologies Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
KR102501920B1
(ko)
|
2013-10-02 |
2023-02-20 |
메디뮨 엘엘씨 |
중화 항-인플루엔자 a 항체 및 이의 용도
|
|
TN2016000137A1
(en)
|
2013-10-18 |
2017-10-06 |
Deutsches Krebsforsch |
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
|
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
|
ES3013992T3
(en)
|
2013-11-14 |
2025-04-16 |
Endocyte Inc |
Compounds for positron emission tomography
|
|
TW202446953A
(zh)
|
2013-12-04 |
2024-12-01 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
|
WO2015085210A1
(en)
|
2013-12-06 |
2015-06-11 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
EP3116903A2
(en)
|
2014-03-14 |
2017-01-18 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
|
AU2015244814B2
(en)
|
2014-04-07 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
|
US11760807B2
(en)
|
2014-05-08 |
2023-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
|
|
EA201692287A1
(ru)
|
2014-05-13 |
2017-06-30 |
Чугаи Сеияку Кабушики Каиша |
Антигенсвязывающая молекула, перенаправляющая т-клетки на клетки, обладающие иммуносупрессорной функцией
|
|
EP3142700B1
(en)
*
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
|
RS59643B1
(sr)
|
2014-06-06 |
2020-01-31 |
Bristol Myers Squibb Co |
Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
|
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
AU2015323860B2
(en)
|
2014-09-29 |
2021-05-27 |
Duke University |
Bispecific molecules comprising an HIV-1 envelope targeting arm
|
|
SMT202500415T1
(it)
|
2014-11-07 |
2026-01-12 |
F Hoffmann La Roche Ltd |
Anticorpi per il-6 migliorati
|
|
WO2016081748A2
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
|
PT3221346T
(pt)
|
2014-11-21 |
2020-10-23 |
Bristol Myers Squibb Co |
Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
|
|
TWI808330B
(zh)
|
2014-12-19 |
2023-07-11 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
|
|
CN107207607B
(zh)
|
2014-12-19 |
2021-05-04 |
中外制药株式会社 |
抗-c5抗体及使用方法
|
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
US10188759B2
(en)
|
2015-01-07 |
2019-01-29 |
Endocyte, Inc. |
Conjugates for imaging
|
|
EA201791754A1
(ru)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
|
KR102788389B1
(ko)
|
2015-04-06 |
2025-03-31 |
서브도메인, 엘엘씨 |
드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도
|
|
PT3303396T
(pt)
|
2015-05-29 |
2023-01-30 |
Bristol Myers Squibb Co |
Anticorpos contra ox40 e utilizações dos mesmos
|
|
JP2018524373A
(ja)
|
2015-07-15 |
2018-08-30 |
ザイムワークス，インコーポレイテッド |
薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
|
|
TW202446797A
(zh)
|
2015-09-18 |
2024-12-01 |
日商中外製藥股份有限公司 |
Il-8結合抗體及其用途
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
|
SG11201803956UA
(en)
*
|
2015-12-01 |
2018-06-28 |
Genmab Bv |
Anti-dr5 antibodies and methods of use thereof
|
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
|
KR20180116359A
(ko)
|
2016-02-23 |
2018-10-24 |
세센 바이오, 아이엔씨. |
인터루킨-6의 길항제 제제 및 이의 용도
|
|
SG11201806861SA
(en)
|
2016-03-04 |
2018-09-27 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
TW202342540A
(zh)
|
2016-03-14 |
2023-11-01 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
|
TWI759287B
(zh)
|
2016-03-15 |
2022-04-01 |
日商中外製藥股份有限公司 |
使用ｐｄ－１軸結合拮抗劑和抗ｇｐｃ３抗體治療癌症的方法
|
|
US20190077870A1
(en)
|
2016-03-16 |
2019-03-14 |
Merrimack Pharmaceuticals, Inc. |
Engineered trail for cancer therapy
|
|
GEAP202214922A
(en)
|
2016-04-15 |
2022-02-10 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
AU2017264578A1
(en)
|
2016-05-09 |
2019-01-03 |
Bristol-Myers Squibb Company |
TL1A antibodies and uses thereof
|
|
WO2018013818A2
(en)
|
2016-07-14 |
2018-01-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
US20190330318A1
(en)
|
2016-07-25 |
2019-10-31 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
|
MX2019001458A
(es)
|
2016-08-02 |
2019-07-04 |
Visterra Inc |
Polipeptidos modificados y usos de los mismos.
|
|
RU2766112C2
(ru)
|
2016-08-05 |
2022-02-08 |
Чугаи Сейяку Кабусики Кайся |
Композиция для профилактики или лечения связанных с il-8 заболеваний
|
|
CA3033661A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
GB201619652D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
AU2017363309A1
(en)
|
2016-11-23 |
2019-07-11 |
Bioverativ Therapeutics Inc. |
Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
|
|
WO2018139623A1
(en)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|
|
EP3583124A1
(en)
|
2017-02-17 |
2019-12-25 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
|
CA3054928A1
(en)
|
2017-02-28 |
2018-09-07 |
Bristol-Myers Squibb Company |
Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
|
|
AU2018227807B2
(en)
|
2017-02-28 |
2024-10-10 |
Seagen Inc. |
Cysteine mutated antibodies for conjugation
|
|
US11634495B2
(en)
|
2017-04-07 |
2023-04-25 |
Miltenyi Biotec B.V. & Co. KG |
Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
|
|
CN110536694A
(zh)
|
2017-04-20 |
2019-12-03 |
Atyr 医药公司 |
用于治疗肺部炎症的组合物和方法
|
|
US11168129B2
(en)
|
2017-05-15 |
2021-11-09 |
University Of Rochester |
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
|
|
KR20240149979A
(ko)
|
2017-05-25 |
2024-10-15 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 중쇄 불변 영역을 포함하는 항체
|
|
JP7710827B2
(ja)
*
|
2017-06-05 |
2025-07-22 |
ヤンセン バイオテツク，インコーポレーテツド |
非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
|
|
RS61883B1
(sr)
*
|
2017-09-19 |
2021-06-30 |
Tillotts Pharma Ag |
Varijante antitela
|
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
WO2019098212A1
(en)
|
2017-11-14 |
2019-05-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
AU2018369639C1
(en)
|
2017-11-14 |
2025-04-03 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
IL274677B2
(en)
|
2017-11-14 |
2025-01-01 |
Arcellx Inc |
Therapies with multifunctional immune system cells
|
|
CA3085785A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Anti-lrp5/6 antibodies and methods of use
|
|
WO2019126399A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Anti-frizzled antibodies and methods of use
|
|
JP7330977B2
(ja)
|
2017-12-19 |
2023-08-22 |
スロゼン オペレーティング， インコーポレイテッド |
Ｗｎｔサロゲート分子及びその使用
|
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
US20210107988A1
(en)
*
|
2018-01-24 |
2021-04-15 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
JP2018138022A
(ja)
*
|
2018-02-23 |
2018-09-06 |
ゲンマブ ビー．ブイ． |
ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
|
|
CN112119090B
(zh)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
|
WO2019183040A1
(en)
|
2018-03-21 |
2019-09-26 |
Five Prime Therapeutics, Inc. |
ANTIBODIES BINDING TO VISTA AT ACIDIC pH
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
|
WO2019204335A1
(en)
|
2018-04-17 |
2019-10-24 |
Endocyte, Inc. |
Methods of treating cancer
|
|
JP7402541B2
(ja)
|
2018-05-03 |
2023-12-21 |
ユニバーシティ オブ ロチェスター |
抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
|
|
WO2019235426A1
(ja)
*
|
2018-06-04 |
2019-12-12 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
|
CN120623353A
(zh)
|
2018-07-05 |
2025-09-12 |
瑟罗泽恩奥普瑞汀公司 |
多特异性wnt替代分子和其用途
|
|
PE20211604A1
(es)
|
2018-07-09 |
2021-08-23 |
Five Prime Therapeutics Inc |
Anticuerpos de union a ilt4
|
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
EP3826666A4
(en)
|
2018-07-26 |
2022-05-11 |
Atyr Pharma, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NRP2-ASSOCIATED DISEASES
|
|
IL280720B2
(en)
|
2018-08-10 |
2025-04-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CD137 antigen binding molecule and use thereof
|
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
|
SG11202103064YA
(en)
|
2018-10-29 |
2021-05-28 |
Hoffmann La Roche |
Antibody formulation
|
|
CN113348177A
(zh)
|
2018-11-28 |
2021-09-03 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
|
US12351622B2
(en)
|
2018-12-05 |
2025-07-08 |
Bica Therapeutics Inc. |
Modified product of Fc domain of antibody
|
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
|
KR20230128134A
(ko)
|
2019-01-22 |
2023-09-01 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
|
|
CN121159688A
(zh)
|
2019-03-19 |
2025-12-19 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
|
US20220195052A1
(en)
|
2019-04-08 |
2022-06-23 |
Biogen Ma Inc. |
Anti-integrin antibodies and uses thereof
|
|
ES3009719T3
(en)
|
2019-04-18 |
2025-03-31 |
Bristol Myers Squibb Co |
Ipilimumab variants with enhanced specificity for binding at low ph
|
|
BR112021021689A2
(pt)
|
2019-05-15 |
2022-03-22 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação a antígeno, composição farmacêutica, e método
|
|
EP3972627A4
(en)
|
2019-05-20 |
2023-06-21 |
Endocyte, Inc. |
Methods for preparing psma conjugates
|
|
WO2021006328A1
(en)
|
2019-07-10 |
2021-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
|
US20220372139A1
(en)
|
2019-07-15 |
2022-11-24 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
|
CN114144435B
(zh)
|
2019-07-15 |
2024-06-25 |
百时美施贵宝公司 |
针对人trem-1的抗体及其用途
|
|
MX2022003204A
(es)
|
2019-09-19 |
2022-04-18 |
Bristol Myers Squibb Co |
Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
|
|
WO2021202235A1
(en)
|
2020-04-01 |
2021-10-07 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
|
CN115397990A
(zh)
|
2020-04-01 |
2022-11-25 |
协和麒麟株式会社 |
抗体组合物
|
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
|
JP2023523480A
(ja)
|
2020-04-28 |
2023-06-06 |
ザ ロックフェラー ユニバーシティー |
中和抗ｓａｒｓ－ｃｏｖ－２抗体およびその使用方法
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
JP7048665B2
(ja)
*
|
2020-05-22 |
2022-04-05 |
ゲンマブ ビー．ブイ． |
ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
|
|
EP4166574A4
(en)
|
2020-06-10 |
2025-01-15 |
Bica Therapeutics Inc. |
FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE
|
|
WO2022010652A1
(en)
*
|
2020-07-10 |
2022-01-13 |
Invetx Inc. |
Compositions for increasing half-life of a therapeutic agent in felines and methods of use
|
|
TW202227481A
(zh)
|
2020-11-04 |
2022-07-16 |
美國洛克菲勒大學 |
中和抗sars-cov-2抗體
|
|
WO2022127793A1
(zh)
|
2020-12-18 |
2022-06-23 |
珠海泰诺麦博生物技术有限公司 |
呼吸道合胞病毒特异性结合分子
|
|
JP2024500920A
(ja)
|
2020-12-23 |
2024-01-10 |
カンタージア アクチエボラーグ |
抗ｉｌ１ｒａｐ抗体
|
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
|
CN117425484A
(zh)
|
2021-03-26 |
2024-01-19 |
阿奇利克斯股份有限公司 |
多功能免疫细胞疗法
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
US20240218057A1
(en)
|
2021-05-06 |
2024-07-04 |
The Rockefeller University |
Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
|
|
EP4408468A4
(en)
|
2021-09-28 |
2025-07-02 |
Frontaim Biomedicines Inc |
MULTIPLE FORMATS OF MOLECULAR COMPLEXES
|
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
|
WO2023191766A1
(en)
*
|
2022-03-28 |
2023-10-05 |
Intervexion Therapeutics, Llc |
ANTIBODIES WITH ALTERED FcRn AFFINITY
|
|
AR129991A1
(es)
|
2022-07-22 |
2024-10-23 |
Bristol Myers Squibb Co |
Anticuerpos que se unen a la pad4 humana y usos de los mismos
|
|
WO2024107749A1
(en)
|
2022-11-16 |
2024-05-23 |
Attralus, Inc. |
Fusion proteins that bind amyloid and the transferrin receptor and uses thereof
|
|
TW202500583A
(zh)
*
|
2023-03-17 |
2025-01-01 |
美商美國禮來大藥廠 |
Pd-1促效劑抗體及以pd-1促效劑抗體治療發炎或自體免疫皮膚疾病之方法
|
|
WO2024200573A1
(en)
|
2023-03-27 |
2024-10-03 |
LAVA Therapeutics N.V. |
Nectin-4 binding agents and methods of use
|
|
KR20260007604A
(ko)
|
2023-05-05 |
2026-01-14 |
오츠카 세이야쿠 가부시키가이샤 |
항-il1rap 항체
|
|
WO2025012118A2
(en)
|
2023-07-07 |
2025-01-16 |
LAVA Therapeutics N.V. |
5t4 binding agents and methods of use
|
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
|
WO2025026282A1
(en)
*
|
2023-07-29 |
2025-02-06 |
Shanghai Kaijin Biotechnology, Ltd |
Modified type e multi-specific antibodies
|
|
WO2025072888A2
(en)
|
2023-09-28 |
2025-04-03 |
Novavax, Inc. |
Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
WO2025088546A1
(en)
*
|
2023-10-25 |
2025-05-01 |
Ablynx N.V. |
Fc domain variants with enhanced fc receptor binding
|
|
WO2025155877A2
(en)
|
2024-01-18 |
2025-07-24 |
The Regents Of The University Of California |
Antibodies binding to pad4 and uses thereof
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
EP4658320A1
(en)
|
2024-02-27 |
2025-12-10 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
EP4653010A1
(en)
|
2024-05-14 |
2025-11-26 |
35Pharma Inc. |
Activin receptor type iib traps for use in improving body composition
|
|
WO2025245176A1
(en)
|
2024-05-22 |
2025-11-27 |
Bristol-Myers Squibb Company |
Multispecific antibody constructs
|
|
WO2025255405A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Anti-fap antibodies and uses thereof
|
|
WO2025255349A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Multispecific anti-cd40 / anti-fap antibodies and uses thereof
|